WELLNESS VS SCIENCE.WELLNESS VS SCIENCE.

Following the indulgence of December, January is characteristically the time when people hyperfocus on their health. With reduced alcohol consumption, increased exercise and the adoption of new diets, the beginning of the year is often dominated by the latest health trends and heavily marketed dietary supplements. With increasingly sophisticated research and manufacturing techniques, the line between wellness and health is becoming ever more blurred, as supplements increasingly claim to offer everything from immune boosts to gut health. The longevity of many such trends is often fleeting – juice cleanses, crystal healing and detox teas have all faded into memory⁽¹⁾. One trend, however, continues to gain traction: the probiotics boom. As the boundaries between wellness fads and scientifically-backed health solutions become increasingly unclear, it raises the question: how should we approach the regulation of supplements such as probiotics in this rapidly evolving landscape?

Drivers of rapid market growth

In the case of probiotics, it is helpful to understand what they are and why they have become so popular. Probiotics are defined as live microorganisms that, when administered in adequate amounts, confer health benefits to the host⁽²⁾.

Probiotics are supported by a large body of evidence demonstrating their therapeutic relevance across various health conditions. Research has shown that probiotics can help alleviate neuropsychiatric disorders, reducing anxiety and improving mood⁽³⁾, aid in gastrointestinal health by preventing pathogen growth⁽⁴⁾, support recovery from upper respiratory diseases, including COVID-19⁽⁵⁾, and even assist in managing obesity, with studies showing reduced body weight and improved quality of life⁽⁶⁾ – just to name a few examples. As research extols the health benefits of probiotics, it fuels market growth by increasing public awareness and interest in their potential.

In this way, evidence supporting these health benefits has been preceded by the commercialisation of probiotic research, which has led to the proliferation of over-the-counter (OTC) probiotic products. Many of these are food or dietary supplements commonly advertised across social media platforms⁽⁷⁾. Additionally, the surge in probiotic popularity can be attributed to increased consumer awareness of the gut's crucial role in overall health⁽⁸⁾. This trend aligns with broader interests in preventive healthcare, gut health and weight management, particularly within Western societies^(9,10).

Another key factor driving the rapid market growth is the regulatory landscape: most countries classify probiotic products as dietary supplements, meaning they are not subjected to the same rigorous approval processes as pharmaceuticals^(11,12). However, given the large body of positive research on probiotics, there are concerns that inadequate regulatory frameworks could limit and ultimately undermine their full potential^(13,14).

Regulating the boom:

Despite the enthusiasm from both consumers and researchers, there is a real concern that the lack of standardised, robust regulations could limit the long-term effectiveness and safety of probiotics. Healthcare professionals in particular are raising alarms about the absence of international standards and the potential risks this poses, not just to the credibility of the probiotic market as a whole, but also to public safety.

A key concern regarding the longevity of probiotics is the semantic drift surrounding the term ‘probiotic’, with some arguing it has been misused in under-regulated markets⁽¹³⁾. With recurring reports of poorly regulated probiotic products mislabelling bacterial strains or making unsupported health claims, confidence in OTC probiotics as well as pharmaceutical probiotics (those intended for disease mitigation or treatment) is being undermined. As a result, this has led to a plateau in progress and raised concerns about a future decline in investment and research into this field⁽¹⁴⁾.

Not only can inadequate regulations limit the market potential of probiotics, but they can also cause harm to consumers. Although regulations vary widely across countries, most probiotic products are classified as OTC dietary supplements rather than drug treatments and this classification allows them to bypass the rigorous standards applied to pharmaceuticals^(11,12). As a result, these supplements don’t undergo a benefit-to-risk ratio or safety profile assessment, leaving potential negative outcomes undiscovered⁽¹⁵⁾. In turn, probiotic supplements aren’t subject to the same rigorous manufacturing and testing standards as drug treatments⁽¹⁶⁾. Under the current frameworks, dietary probiotics are intended for use by the general healthy population, yet confusion among healthcare professionals and the public has led to their inappropriate use in vulnerable groups.

The consequences of such regulatory leniency are far from hypothetical. One of the most tragic examples occurred in 2014, when a preterm infant in Connecticut died from gastrointestinal mucormycosis, caused by a contaminated ABC Dophilus dietary supplement. Despite being marketed as containing three bacterial strains with probiotic effects and intended for use in children and infants within healthcare settings, the supplement was not regulated as a pharmaceutical. This case highlights how inadequate oversight of dietary supplements allowed an illegal biological product to enter the market, with poor manufacturing going unchecked⁽¹⁷⁾. Even more concerning, nearly a decade later, following another infant fatality, the FDA issued a press release warning about the potential risks posed by probiotic-containing products to preterm infants⁽¹⁸⁾. Yet, the regulatory framework for dietary probiotics has remained largely unchanged.

Inadequate regulations are not confined to the US. While the UK and the majority of the EU require probiotic products to have an approved health claim, this doesn’t prevent companies avoiding restrictions through alternative labels such as ‘live bacteria’ or ‘biotic’^(11,12). In reflection of Europe’s approach, the ESPGHAN working group for probiotics and prebiotics acknowledges the plethora of evidence supporting clinical probiotic use, but emphasises that without pharmaceutical-level regulatory checkpoints, the current safety measures for dietary probiotics aren’t sufficient for clinical use⁽¹⁹⁾.

The path forward

As a medical communication agency, we are well-versed in the challenges posed by complex and evolving compliance regulations. The probiotic market is a prime example of how advancing science, consumer demand and regulatory frameworks must align. To ensure public safety, there is an urgent need for clearer communication that distinguishes between OTC and clinical probiotics. If the growing social and economic demand for probiotics persists, regulatory frameworks will need to evolve in a way that balances the interests of all stakeholders. As the probiotic boom has continued its surge this January, outpacing the formation of necessary regulation, we believe honest communication is more crucial than ever. We encourage consumers to stay informed, speak with medical professionals and think critically before jumping on the next wellness trend.

By Evie Lane

References

1. 13 ‘Woo Woo’ Trends That Are More Quackery Than Wellness Cure-All – Vitally You. Accessed December 21, 2025. https://vitallyyou.co/2025/03/21/13-woo-woo-trends-were-done-with-these-arent-a-wellness-cure-all/
2. Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, et al. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nature Reviews Gastroenterology & Hepatology. 2014 Aug 1;11(8):506–14.
3. Johnson KVA, Steenbergen L. Probiotics reduce negative mood over time: the value of daily self-reports in detecting effects. npj Mental Health Research. 2025 Apr 9;4(1):10.
4. Ferrari S, Mulè S, Parini F, Galla R, Ruga S, Rosso G, et al. The influence of the gut-brain axis on anxiety and depression: A review of the literature on the use of probiotics. Journal of Traditional and Complementary Medicine. 2024 May 1;14(3):237–55.
5. Chau CHH, Stefler D, Szeto MMS. Effectiveness of probiotics on COVID-19 prevention and treatment against mild COVID-19 in outpatient care: A systematic review. Nutr Health. 2025 Sep 26;02601060251378200.
6. Michael DR, Jack AA, Masetti G, Davies TS, Loxley KE, Kerry-Smith J, et al. A randomised controlled study shows supplementation of overweight and obese adults with lactobacilli and bifidobacteria reduces bodyweight and improves well-being. Sci Rep. 2020 Mar 6;10(1):4183.
7. Lei G, Khan A, Budryn G, Grzelczyk J. Probiotic products from laboratory to commercialization. Trends in Food Science & Technology. 2025 Jan 1;155:104807.
8. Uhegwu CC, Anumudu CK. Probiotic Potential of Traditional and Emerging Microbial Strains in Functional Foods: From Characterization to Applications and Health Benefits. Microorganisms. 2025;13(11).
9. Fredua-Agyeman M, Larbi EA. Inaccurate labelling practices in probiotic products: A regulatory shortfall in Accra, Ghana. PLOS ONE. 2025 May 28;20(5):e0322194.
10. Anna P, Jonathan M, Kristi W, Shaun C, Stefan R, Hayley D, et al. The $2 trillion global wellness market gets a millennial and Gen Z glow-up. The Future of Wellness trends survey 2025 | McKinsey. Accessed January 5, 2026. https://www.mckinsey.com/industries/consumer-packaged-goods/our-insights/future-of-wellness-trends
11. Spacova I, Binda S, ter Haar JA, Henoud S, Legrain-Raspaud S, Dekker J, et al. Comparing technology and regulatory landscape of probiotics as food, dietary supplements and live biotherapeutics. Front Microbiol. 2023 Dec 19;14:1272754.
12. GOV.UK. Nutrition and health claims: guidance to compliance with Regulation (EC) 1924/2006. Accessed December 21, 2025. https://www.gov.uk/government/publications/nutrition-and-health-claims-guidance-to-compliance-with-regulation-ec-1924-2006-on-nutrition-and-health-claims-made-on-foods/nutrition-and-health-claims-guidance-to-compliance-with-regulation-ec-19242006
13. Stuivenberg GA. Probiotics, Placebos, or Profits? Reclaiming Scientific Language in the Age of Commercialized Microbes. Applied Microbiology. 2025;5(4).
14. Wiegers C, van Beek EHT, Larsen OFA. Clinical research with probiotics as an indicator of global valorization since the year 2000. Frontiers in Microbiology. 2023;Volume 14-2023.
15. D’Agostin M, Squillaci D, Lazzerini M, Barbi E, Wijers L, Lozzo PD, et al. Invasive Infections Associated with the Use of Probiotics in Children: A Systematic Review. Children. 2021 Oct 15 [cited 2026 Jan 8];8(10).
16. de Simone C. The Unregulated Probiotic Market. Clinical Gastroenterology and Hepatology. 2019 Apr 1;17(5):809–17.
17. Vallabhaneni S, Walker TA, Lockhart SR, Ng D, Chiller T, Melchreit R, et al. Fatal Gastrointestinal Mucormycosis in a Premature Infant Associated with a Contaminated Dietary Supplement — Connecticut, 2014. MMWR Morb Mortal Wkly Rep. 2015 Feb 20;64(6):155–6.
18. Commissioner O of the. FDA. FDA; 2024. FDA Raises Concerns About Probiotic Products Sold for Use in Hospitalized Preterm Infants. Accessed January 5, 2026. https://www.fda.gov/news-events/press-announcements/fda-raises-concerns-about-probiotic-products-sold-use-hospitalized-preterm-infants
19. Kolaček S, Hojsak I, Berni Canani R, Guarino A, Indrio F, Orel R, et al. Commercial Probiotic Products. Journal of Pediatric Gastroenterology and Nutrition. 2017;65(1):117–24.